Abstract
Collaborations and Licensing in Global Pharmaceuticals and Biotech new industry report
Industry developments of the last 10 years have changed the shape of your industry. Discovering
and bringing one new drug to market typically costs a pharmaceutical or biotechnology company nearly
$900 million and takes an average of 10 to 12 years. Economic pressures have forced collaborations,
as larger pharmaceutical companies cannot develop enough new compounds to sustain a high percentage
growth.
In the past 10 years partnership collaborations between big pharmaceutical companies and biotech
companies have increased by 359 per cent, to the current situation where nearly a third of new
products are developed through collaborations. The year 2003 saw many blockbuster drugs come off
patent and the fact that 5 major pharmaceutical firms have no billion-dollar blockbusters in late
stage development highlights the increasing importance of these alliances.
Pharmaceutical companies derived an average 20% of total sales from in-licensing deals in 2003,
by 2009 this figure is expected to reach 40%. Collaborations and joint ventures are an important
ingredient to success in the pharmaceutical and biotechnology sectors, current trends suggest that
their importance will grow in the future.
Collaborations and licensing in pharma and biotech assesses the current financial state of the
pharmaceutical and biotechnology industries and provides key statistics on collaboration and
licensing deals. In addition, five-year forecasts on the future of collaboration and licensing deals
are provided as well as analysis of the past and the most recent deals.
A special Visiongain chapter delves into the costs involved in collaboration, the issues behind
entering into deals and provides insight on developing the skills needed to attract partners and
subsequent alliance management. Visiongain also provides a list of biotech and pharma company
profiles.
Collaborations and licensing in pharma and biotech addresses the following key issues that are
vital for anyone interested in this field:
- Current pharmaceutical and biotechnology industries
- The drug discovery process
- Different types of partnership
- A review of collaborations and licensing deals by therapeutic area
- Recommendations for optimising partnering strategy
- The future of pharma and biotech collaboration and licensing deals.
Analysis includes the use of charts and graphs showing trends in collaboration and licensing
deals in the marketplace. Company specific information including sales and revenue figures and
research and development trends are provided throughout the report.
View Cart
